Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia

Alessandra Iurlo(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Umberto Gianelli(University of Milan), Juri Alessandro Giannotta(University of Milan), Nicola Orofino(Azienda Ospedaliera Ospedale Civile di Legnano), Daniele Cattaneo(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Manuela Zappa(Ospedale Maggiore), Cristina Bucelli(University of Milan)
Annals of Hematology
August 19, 2017
10.1007/s00277-017-3105-8
Cited by 9

Related Papers

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
|Blood|2009|433
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
|Journal of Clinical Oncology|2016|394
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
Angiogenesis in myelodysplastic syndromes
|British Journal of Cancer|1999|272